Langerhans Cell Histiocytosis (LCH): Diagnosis & Treatment

Langerhans Cell Histiocytosis (LCH) is a rare clonal neoplastic disorder in which abnormal cells resembling the skin's Langerhans cells accumulate in tissues, forming destructive lesions. It is not a cancer in the traditional sense but is now classified as a neoplasm due to recurrent somatic mutations (most commonly BRAF V600E) that drive uncontrolled cell proliferation. LCH can affect a single organ (usually bone) or multiple organ systems simultaneously.

In children, the most common early signs include a painful or swollen area of the skull or another bone, a persistent scalp rash resembling severe cradle cap, chronic ear discharge that does not respond to antibiotics, and unexplained polyuria and polydipsia (excessive thirst and urination) due to diabetes insipidus. In infants, disseminated LCH can present with a widespread skin rash, liver and spleen enlargement, and pallor from anaemia. Any child with unexplained bone pain, unusual scalp changes, or diabetes insipidus should be investigated for LCH.

LCH is classified by the WHO as a neoplastic disorder — not a classic cancer but not a purely inflammatory condition either. It arises from a somatic mutation (most often BRAF V600E) in a haematopoietic precursor cell, leading to clonal proliferation. The behaviour ranges from self-limiting to aggressive, and multisystem LCH involving risk organs (liver, spleen, bone marrow) can be life-threatening and requires systemic treatment similar to cancer therapy.

BRAF V600E is a specific mutation found in approximately 55% of LCH cases. It causes constitutive activation of a signalling pathway (MAPK/ERK) that drives abnormal cell growth. A positive BRAF V600E result is clinically important because it: (1) confirms the neoplastic nature of the disease, (2) is associated with higher risk of CNS and pituitary involvement and disease reactivation, and (3) makes the patient potentially eligible for BRAF inhibitor drugs (vemurafenib, dabrafenib) in refractory or high-risk disease.

LCH is diagnosed by tissue biopsy showing characteristic histiocytic cells with folded nuclei that stain positive for CD1a and Langerin (CD207) on immunohistochemistry. Molecular testing for BRAF V600E and other MAPK mutations should be performed on the biopsy sample. Systemic staging — whole-body MRI or PET-CT, MRI brain with gadolinium, blood tests including liver function and full blood count, and urine osmolality testing — is mandatory after a positive biopsy to determine disease extent and risk-organ involvement.

The international standard for multisystem LCH is the LCH-III/LCH-IV protocol: induction with weekly intravenous vinblastine plus oral prednisolone for 12 weeks, followed by continuation therapy for 12 months with vinblastine pulses, prednisolone pulses, daily oral mercaptopurine, and methotrexate. For risk-organ positive disease with a poor response, salvage regimens including cladribine plus cytarabine (CLARC) are used. BRAF V600E-positive refractory disease is treated with BRAF inhibitors (vemurafenib or dabrafenib ± trametinib).

Yes. Diabetes insipidus (DI) is one of the most common long-term complications of LCH, occurring in approximately 15–25% of multisystem cases. It results from LCH infiltration of the hypothalamus and posterior pituitary, disrupting antidiuretic hormone (ADH/vasopressin) production. DI presents as excessive thirst and very large volumes of dilute urine. Unfortunately, DI from LCH is rarely reversible once established, and lifelong desmopressin (DDAVP) replacement is required. Regular endocrine follow-up is essential for all survivors.

Neurodegenerative LCH (ND-LCH) is a distinct and serious complication in which LCH causes progressive neurological damage — typically affecting the cerebellum, basal ganglia, and brainstem — leading to ataxia, dysarthria, cognitive difficulties, and behavioural changes. It is strongly associated with BRAF V600E mutation. Unlike active LCH mass lesions in the brain, ND-LCH represents a neuroinflammatory-neurodegenerative process. BRAF inhibitors (vemurafenib, dabrafenib) have shown some stabilisation in small series, though the full extent of reversibility remains under investigation.

Yes. Reactivation (relapse) of LCH is common — occurring in approximately 30–50% of multisystem cases, most frequently in the first two years after completing treatment. Risk-organ positive disease and BRAF V600E positivity are associated with higher reactivation rates. Reactivation in the same or new sites may be treated with salvage chemotherapy or, in BRAF V600E-positive cases, BRAF inhibitors. Long-term follow-up and regular clinical review are essential for all patients with multisystem LCH.

Yes. CancerFax supports patients and families navigating LCH by reviewing medical records and biopsy reports to confirm diagnosis and molecular findings (BRAF V600E, MAP2K1), identifying access to BRAF and MEK inhibitors (vemurafenib, dabrafenib, trametinib) through specialist centres in India, China, and Europe, facilitating second opinions from expert histiocytosis and rare haematology oncologists, and coordinating clinical trial matching for refractory or high-risk disease. Send your reports to begin a personalised review.